"HIV Long Terminal Repeat" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Regulatory sequences important for viral replication that are located on each end of the HIV genome. The LTR includes the HIV ENHANCER, promoter, and other sequences. Specific regions in the LTR include the negative regulatory element (NRE), NF-kappa B binding sites , Sp1 binding sites, TATA BOX, and trans-acting responsive element (TAR). The binding of both cellular and viral proteins to these regions regulates HIV transcription.
Descriptor ID |
D016325
|
MeSH Number(s) |
G02.111.570.080.708.850.400 G05.360.080.708.850.400
|
Concept/Terms |
HIV Long Terminal Repeat- HIV Long Terminal Repeat
- LTR, Human Immunodeficiency Virus
- Human Immunodeficiency Virus LTR
- Long Terminal Repeat, HIV
- Human Immunodeficiency Virus Long Terminal Repeat
Trans-Acting Responsive Region, HIV- Trans-Acting Responsive Region, HIV
- Trans Acting Responsive Region, HIV
- HIV Trans-Acting Responsive Region
- HIV Trans Acting Responsive Region
- Trans-Activation Responsive Element, HIV
- Trans Activation Responsive Element, HIV
- Trans-Activation Responsive Region, HIV
- Trans Activation Responsive Region, HIV
- TAR Element, HIV
- HIV TAR Element
- HIV TAR Elements
- TAR Elements, HIV
Sp1-Binding Site, HIV- Sp1-Binding Site, HIV
- Sp1 Binding Site, HIV
- HIV Sp1-Binding Site
- HIV Sp1 Binding Site
- HIV Sp1-Binding Sites
- Sp1-Binding Sites, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Long Terminal Repeat".
Below are MeSH descriptors whose meaning is more specific than "HIV Long Terminal Repeat".
This graph shows the total number of publications written about "HIV Long Terminal Repeat" by people in this website by year, and whether "HIV Long Terminal Repeat" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2011 | 1 | 1 | 2 |
2017 | 1 | 4 | 5 |
2018 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Long Terminal Repeat" by people in Profiles.
-
Human immunodeficiency virus 1 dual-target nucleic acid technology improves blood safety: 5 years of experience of the German Red Cross blood donor service Baden-Württemberg-Hessen. Transfusion. 2018 12; 58(12):2886-2893.
-
Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir. BMC Biol. 2018 07 11; 16(1):75.
-
Regulatory CD4 T cells inhibit HIV-1 expression of other CD4 T cell subsets via interactions with cell surface regulatory proteins. Virology. 2018 03; 516:21-29.
-
Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. PLoS One. 2017; 12(10):e0187095.
-
Crosstalk between histone modifications indicates that inhibition of arginine methyltransferase CARM1 activity reverses HIV latency. Nucleic Acids Res. 2017 Sep 19; 45(16):9348-9360.
-
New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification. J Clin Microbiol. 2017 09; 55(9):2850-2857.
-
Conserved presence of G-quadruplex forming sequences in the Long Terminal Repeat Promoter of Lentiviruses. Sci Rep. 2017 05 17; 7(1):2018.
-
Interferon-inducible LY6E Protein Promotes HIV-1 Infection. J Biol Chem. 2017 03 17; 292(11):4674-4685.
-
Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis. 2012 Feb 01; 54(3):451-3.
-
Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy. PLoS One. 2011; 6(6):e21081.